Comparing SG&A Expenses: Genmab A/S vs Amphastar Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Amphastar Pharmaceuticals, Inc. over the past decade.

Key Insights

From 2014 to 2023, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Amphastar Pharmaceuticals, Inc. has maintained a more conservative growth of approximately 100% in the same period.

Strategic Implications

Genmab's substantial rise in expenses suggests a strategic focus on scaling operations and market presence, while Amphastar's steady increase indicates a more measured approach. Investors and stakeholders should consider these trends when evaluating the companies' future growth potential and market strategies.